+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Hematology Request for Proposals

Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine is pleased to announce a Request for Proposals (RFP) focused on supporting implementation science–driven initiatives within community-based health care organizations aimed at optimizing the treatment and care of patients with relapsed/refractory multiple myeloma (RR/MM) who may be eligible for chimeric antigen receptor (CAR) T-cell therapy

The overarching goal of this initiative is to support the application of evidence-based practices through harmonized educational, operational, and collaborative strategies. Successful proposals will demonstrate how education is embedded within broader implementation efforts and how these combined approaches lead to measurable improvements in care processes, clinician behavior, and patient outcomes for individuals with RR/MM.

The Implementation Science grants are intended to support projects aimed at improving patient outcomes in areas where medical needs are not fully met. These are different from general research grants, which primarily focus on generating new knowledge and evidence through systematic investigation.

Under this RFP, projects should focus on implementing and evaluating practice-level or systemlevel changes and embedding certified education (CME/CE) to facilitate adoption, appropriate use, and sustainability of evidence-based care.

It is the expectation that findings from your project will be disseminated to the healthcare community via posters, abstracts, white papers, publications, or similar scholarly professional communications.

The implementation science grants fall under the auspices of independent medical education. Accordingly, Johnson & Johnson will have no control or influence over the design or conduct of funded projects, the content of educational activities, or the selection of faculty or authors.

Grant ApplicationDeadline: July 15, 2026

Target Audience: Community Hematologist/Oncologists, Academic Hem/Oncs (to serve as mentors to community practices)

Project Timelines: Programs start date should be on or after September 1, 2026 and can run up to 18 months.

Funding Limits: Up to $275,000, lower cost projects will be prioritized. Grant payments will be made in full

AI Based Application Success Predictor

💊 1. Strong Alignment with Strategic Therapeutic Areas (Non-Negotiable)

Competitive proposals almost always align with key portfolio areas such as:

Oncology
Immunology
Neuroscience
Pulmonary hypertension
Infectious disease
Cardiovascular/metabolic disease

👉 Projects outside strategic pipeline interests → low success probability

🎯 2. Clear Clinical Impact & Therapeutic Relevance (Top Predictor)

Johnson & Johnson Innovative Medicine strongly prioritizes:
- Research that can:
  - Improve treatment outcomes
  - Optimize therapy use
  - Address unmet clinical needs

👉 Key question:
“Will this meaningfully improve patient care or therapeutic strategy?”

🔄 3. Translational & Precision Medicine Focus (Critical)

One of the strongest recurring themes:

Translational medicine
Biomarker-guided therapy
Precision treatment selection
Molecularly stratified care

👉 Pure exploratory science without therapeutic translation is generally less competitive.

🧬 4. Biomarker & Real-World Evidence Integration (Major Differentiator)

High-success proposals often include:

Biomarker discovery/validation
Genomic profiling
Real-world outcomes
Companion diagnostics
Treatment-response prediction

👉 Data-rich precision approaches are strongly favored.

🚀 5. Innovation in Advanced Therapeutics

Priority innovation areas include:

Cell and gene therapy
Immunotherapy
Bispecific antibodies
AI-enabled clinical care
Digital therapeutics
Novel drug combinations

👉 Innovation must demonstrate:

clinical applicability
translational scalability

🧪 6. Strong Scientific Rigor & Operational Feasibility

Industry-supported studies are heavily evaluated for:

Methodological quality
Recruitment feasibility
Timeline realism
Regulatory readiness
Data integrity systems

👉 Operational execution capability is critical.

👨‍⚕️ 7. Strong Investigator & Institutional Track Record

Competitive applicants usually have:

Prior clinical trial leadership
Strong publication history
Access to target patient populations
Established translational infrastructure

👉 Experienced clinical investigators have a major advantage.

🤝 8. Collaboration Readiness & Industry Partnership Capability

Strong proposals demonstrate:

Understanding of:
- GCP standards
- pharmacovigilance
- regulatory compliance
- multicenter coordination

👉 Professional collaboration readiness significantly improves competitiveness.

🌍 9. Focus on Unmet Medical Need & Difficult Disease Areas

High-priority themes include:

Resistant disease
Rare disease
Severe inflammatory disease
Advanced cancers
High-burden chronic disease

👉 Addressing unmet need increases strategic value.

📊 10. Strong Patient-Centered Outcomes & Healthcare Value

Increasing emphasis on:

Quality of life
Patient-reported outcomes
Adherence
Healthcare utilization
Value-based care evidence

👉 Real-world healthcare impact matters strongly.

📈 11. Potential for Clinical Adoption & Guideline Influence

Competitive studies often:

Generate:
- practice-changing evidence
- trial-enabling data
- publication potential
- treatment optimization insights

👉 Dissemination and adoption potential improve funding likelihood.

🌐 12. Data Science & Digital Health Integration

Growing priority areas include:

AI-assisted decision support
Digital monitoring
Real-world data platforms
Predictive analytics

👉 Technology-enabled translational studies are increasingly competitive.

📊 Summary: Key Predictors (Ranked)

🔥 Highest impact factors:

Alignment with therapeutic portfolio
Clinical/translational relevance
Precision medicine and biomarker integration

⚖️ Major differentiators:

Innovation in advanced therapeutics
Strong operational feasibility
Investigator/institutional expertise

📌 Supporting factors:

Industry collaboration readiness
Unmet medical need focus
Patient-centered outcomes
Digital/data integration

💡 Insider Insight

Compared to NIH or nonprofit funders:

Johnson & Johnson Innovative Medicine is:
👉 highly focused on:
- translational implementation
- precision medicine
- clinically actionable evidence
- operational reliability
- scalable therapeutic innovation

👉 Winning formula:
Precision-focused translational study + strong clinical relevance + operational excellence + alignment with therapeutic strategy

✔️ What wins:

Biomarker-driven oncology/immunology research
Real-world evidence studies
Advanced therapeutic and precision medicine projects
Translational studies addressing unmet clinical need
AI/data-enhanced clinical research

❌ What struggles:

Pure basic science
Weak operational feasibility
Non-strategic therapeutic areas
Limited clinical applicability

Specialties

Cancer

Oncology

Hematology

Pharmaceuticals

Eligibility Requirements

This RFP is open to community cancer centers and healthcare institutions with experience in treating multiple myeloma. Collaborative proposals involving multiple institutions or disciplines are highly encouraged. Eligible applicants include academic institutions (medicine, pharmacy, nursing), teaching hospitals, medical societies or professional associations, government agencies, and medical education companies.

Interested clinicians are encouraged to work closely with their institution’s office of Continuing Medical Education or an ACCME accredited organization and not their research departments.. Requests must be certified for CME/CE credit(s) and the grant application/request must be submitted by the accredited organization.

Clinicians at community cancer centers without an internal CME office may partner with an ACCME-accredited medical society, professional association, or medical education company to develop the proposal and submit the grant application

Sponsor Details

Sponsor Institute/Organizations: Johnson & Johnson Innovative Medicine

Sponsor Type: Corporate/Non-Profit

Address: 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity